A predictive model of therapeutic monoclonal antibody dynamics and regulation by the neonatal Fc receptor (FcRn).
about
Pharmacokinetic models for FcRn-mediated IgG dispositionKey factors influencing ADME properties of therapeutic proteins: A need for ADME characterization in drug discovery and developmentPhysiologically Based Pharmacokinetic (PBPK) Modeling and Simulation Approaches: A Systematic Review of Published Models, Applications, and Model VerificationEffects of anti-VEGF on predicted antibody biodistribution: roles of vascular volume, interstitial volume, and blood flowProjecting human pharmacokinetics of monoclonal antibodies from nonclinical data: comparative evaluation of prediction approaches in early drug development.Emerging Role of the Spleen in the Pharmacokinetics of Monoclonal Antibodies, Nanoparticles and Exosomes.Simulation of monoclonal antibody pharmacokinetics in humans using a minimal physiologically based model.A model-based meta-analysis of monoclonal antibody pharmacokinetics to guide optimal first-in-human study designMultichannel imaging to quantify four classes of pharmacokinetic distribution in tumorsPharmacokinetics of anti-hepcidin monoclonal antibody Ab 12B9m and hepcidin in cynomolgus monkeysQuantitative serial imaging of an 124I anti-CEA monoclonal antibody in tumor-bearing mice.Pharmacokinetics and toxicology of therapeutic proteins: Advances and challenges.Whole-body physiologically based pharmacokinetic models.Dose selection based on physiologically based pharmacokinetic (PBPK) approaches.Application of PBPK modeling to predict monoclonal antibody disposition in plasma and tissues in mouse models of human colorectal cancerAntibody tumor penetration: transport opposed by systemic and antigen-mediated clearance.Second-generation minimal physiologically-based pharmacokinetic model for monoclonal antibodies.Pretargeted molecular imaging and radioimmunotherapy.Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies.Physiologically based pharmacokinetic modeling in drug discovery and development: a pharmaceutical industry perspective.Challenges and considerations for development of therapeutic proteins in pediatric patients.Assessments of antibody biodistribution.Physiologically based pharmacokinetic models of small molecules and therapeutic antibodies: a mini-review on fundamental concepts and applications.Population physiologically-based pharmacokinetic model incorporating lymphatic uptake for a subcutaneously administered pegylated peptide.Potential Sources of Inter-Subject Variability in Monoclonal Antibody Pharmacokinetics.Quantification of IgG monoclonal antibody clearance in tissues.Analysis of a Compartmental Model of Endogenous Immunoglobulin G Metabolism with Application to Multiple Myeloma.Multiscale Modeling of Antibody-Drug Conjugates: Connecting Tissue and Cellular Distribution to Whole Animal Pharmacokinetics and Potential Implications for Efficacy.Impact of altered endogenous IgG on unspecific mAb clearance.Incorporation of FcRn-mediated disposition model to describe the population pharmacokinetics of therapeutic monoclonal IgG antibody in clinical patients.Antigenic burden and serum IgG concentrations influence rituximab pharmacokinetics in rheumatoid arthritis patients.Application of PBPK modelling in drug discovery and development at Pfizer.Tissue expression profile of human neonatal Fc receptor (FcRn) in Tg32 transgenic mice.Pharmacokinetic Time Course Scaling of a Subcutaneously Administered Pegylated Peptide Conjugate for a First-in-Human Investigation.Prediction of the Pharmacokinetics, Pharmacodynamics, and Efficacy of a Monoclonal Antibody, Using a Physiologically Based Pharmacokinetic FcRn Model.Applied Concepts in PBPK Modeling: How to Build a PBPK/PD Model.Development of a physiologically based pharmacokinetic model for a domain antibody in mice using the two-pore theory.Antibody biodistribution coefficients: inferring tissue concentrations of monoclonal antibodies based on the plasma concentrations in several preclinical species and human.Evaluation of a catenary PBPK model for predicting the in vivo disposition of mAbs engineered for high-affinity binding to FcRn.Potential of optimal preloading in anti-CD20 antibody radioimmunotherapy: an investigation based on pharmacokinetic modeling.
P2860
Q27000721-0A41633A-599D-473B-955C-9A6C6377AF45Q28082880-DF2EB6A9-40D0-45F6-841A-1E93FE2BC3EFQ28088352-866BB265-D48A-42D8-92D0-7C113C599674Q28477440-05110804-A0CD-4184-B873-249408332EAFQ30930928-3849F373-F75D-4612-AE68-B69B2597174EQ33838871-72B9E42C-32A5-49D9-8A94-D6B42AB45D8FQ34099756-B42C3248-1041-4F93-84C6-CFDEB4882E41Q34223916-674CB3BF-8A0F-4581-A83C-0DF067D1ED8DQ34241923-6BBFA385-0DC3-42C5-8A02-B33FBDA4E549Q34293733-21C14697-DD08-4524-9FCF-8D7BEE5E5477Q34328761-D1893A44-D7B5-4BEC-8E7F-2029D8117024Q35929084-84A5F712-85E7-42EC-8F08-96EDDF62E66EQ36788418-E1913B51-04F2-44BF-85E1-3ACCEB9FAA26Q36910606-C5935B18-C9DA-4964-9F86-8228FDBF9407Q37054801-54A2D6EF-74C2-4A71-A3FC-324FB5EAC5E4Q37187003-6CB00567-914C-411B-ABF4-30613D6070BDQ37331009-B81FE9FC-0246-4D60-A379-6178F30B1877Q38022016-A9193EDA-02BC-4BD0-BAAA-B1E3EAAB0B19Q38072598-71FEFE36-B67A-4BEC-B344-4E699581B5E7Q38351385-86391928-7D0E-47F7-9EDF-F59CF9E2BA8EQ38364457-E35D2B1A-D6F4-4DEE-B188-F2F13BA4843CQ38364460-5F89560C-1583-4C6E-B098-0E1266E8D832Q38605894-DD23EFB4-A01F-43DE-9CDE-543AD284ACCBQ38705177-EE0D77B2-B873-4264-9338-82D02C62E6BBQ38714339-BDAD6A68-9455-416F-A8A1-CECD939971B3Q38726179-E7EA4D76-B9DD-4940-A6C2-809F6AEB9230Q38736404-D0D80AED-A7B3-4052-98B5-39D968FB94BBQ38765188-85A938E4-458E-47E4-9D7B-A349450742F6Q38821722-B5777C62-4FA2-4CAF-A098-EBE02A5A794DQ38941467-88E507DB-71FF-4DFF-AAEA-E1E14C126569Q38946557-5C86A733-3199-49FF-9299-BB7147741629Q39692575-2A9828DE-06C8-487F-8338-98CF5C3C7170Q39830501-243BBD62-921E-478E-AF61-6C90F97CCF3EQ40030334-DE037B05-B0CF-4DAF-ABCE-34EE3033264EQ41559765-FF46B934-9777-4A31-8AB5-1647D528763CQ41582110-2B54E480-10E8-49C3-90C1-59D7B85A9E08Q41597290-8E46DB43-E86C-4244-8A95-C778C5627934Q41874340-6211E85B-D350-4A44-B009-80C2BFD7B1FAQ41931879-D2061BED-FB06-4115-9920-82BB06CE344CQ41945014-A7267C22-2FA3-40F6-9A2A-4DDA5B4C2A60
P2860
A predictive model of therapeutic monoclonal antibody dynamics and regulation by the neonatal Fc receptor (FcRn).
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
A predictive model of therapeu ...... e neonatal Fc receptor (FcRn).
@en
A predictive model of therapeu ...... on by the neonatal Fc receptor
@nl
type
label
A predictive model of therapeu ...... e neonatal Fc receptor (FcRn).
@en
A predictive model of therapeu ...... on by the neonatal Fc receptor
@nl
prefLabel
A predictive model of therapeu ...... e neonatal Fc receptor (FcRn).
@en
A predictive model of therapeu ...... on by the neonatal Fc receptor
@nl
P2093
P2860
P1476
A predictive model of therapeu ...... e neonatal Fc receptor (FcRn).
@en
P2093
Gregory Z Ferl
Joseph J DiStefano
P2860
P2888
P304
P356
10.1007/S10439-005-7410-3
P577
2005-11-01T00:00:00Z